Determining quantitative targets for public funding of tuberculosis research and development

Health Research Policy and Systems

Volumn 11, Issue 1, 2013, Pages

  Walwyn, David R ^a  

^a UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

HEALTH CARE COST; HUMAN; MEDICAL RESEARCH; REVIEW; SOUTH AFRICA; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; DEVELOPING COUNTRIES; DRUG DISCOVERY; FINANCING, ORGANIZED; HEALTH EXPENDITURES; HUMANS; RESEARCH; SOUTH AFRICA; TUBERCULOSIS;

EID: 84874692706     PISSN: None     EISSN: 14784505     Source Type: Journal    
DOI: 10.1186/1478-4505-11-10     Document Type: Review

References (35)

1. WHO Global tuberculosis control: WHO report 2011 2011, Geneva: WHO, [http://www.who.int/tb/ publications/global_report/en/], WHO.
2. U.S. Global health policy country data [http://www.globalhealthfacts.org/data/topic/map.aspx?ind=12].
3. National Department of Health Strategic plan for TB 2007 to 2011 2007, Pretoria: National Department of Health, [http://www.info.gov.za/view/DownloadFileAction?id=72544], National Department of Health.
4. Day C, Gray A, Budgell E. Health and related indicators. South African Health Review 2011 2011, Durban: Health Systems Trust, Padarath A, English R, [http://www.hst.org.za/publications/south-african-health-review-2011].
5. Grimard F, Harling G. The Impact of Tuberculosis on Economic Growth 2004, Department of Economics: McGill University.
6. National Department of Health Delivery Agreement 2010, Pretoria: National Department of Health, National Department of Health.
7. Sáncheza F, López Colomésa JL, Villarino E, Grosset J. New drugs for tuberculosis treatment. Enferm Infec Microbiol Clin 2011, 29(Suppl 1):47-56.
8. Treatment action group/i-base: 2011 pipeline report 2011, New York: Treatment Action Group, [http://www.treatmentactiongroup.com], .
9. Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez DE, Gao M, Awad M, Park S-K, Shim TS, Suh GY, Danilovits M, Ogata H, Kurve A, Chang J, Suzuki K, Tupasi T, Koh W-J, Seaworth B, Geiter LJ, Wells CD. Delamanid for multidrug-resistant pulmonary tuberculosis. NEJM 2012, 66(23):2151-2160.
10. Global Alliance for TB Drug Development TB Alliance Pipeline 2003, Geneva: TB Alliance, [http://www.tballiance.org/ downloads /Pipeline/ TBA-Pipeline-May-2012.pdf], Global Alliance for TB Drug Development.
11. Stewart JJ, Allison PN, Johnson RS. Putting a price on biotechnology. Nat Biotechnol 2001, 19:813-817. 10.1038/nbt0901-813, 11533634.
12. Global Alliance for TB Drug Development The Economics of TB Drug Development 2001, Geneva: Global Alliance for TB, [http://www.tballiance.org/downloads/publications/ TBA_Economics_Report_Exec.pdf], Global Alliance for TB Drug Development.
13. Gardner CAT, Acharya T, Pablos-Mendez A. The global alliance for tuberculosis drug development -accomplishments and future directions. Clin Chest Med 2005, 26:341-347. 10.1016/j.ccm.2005.02.008, 15837115.
14. Mathieu M. Paraxel's Pharmaceutical R&D statistical sourcebook 2005/2006 2005, Boston: Paraxel International Corporation.
15. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003, 22:151-185. 10.1016/S0167-6296(02)00126-1, 12606142.
16. DiMasi JA, Hansen RW, Grabowski HG, Lasagna L. Cost of innovation in the pharmaceutical industry. J Health Econ 1991, 10:107-142. 10.1016/0167-6296(91)90001-4, 10113009.
17. DiMasi JA, Hansen RW, Grabowski HG. Extraordinary claims require extraordinary evidence. J Health Econ 2005, 24:1034-1044.
18. G-FINDER Neglected disease research and development: is innovation under threat? 2011, London: Policy Cures, [http://policycures.org/index.html], G-FINDER.
19. Jiménez-Levi E. Tuberculosis research and development: 2011 report on tuberculosis research funding trends, 2005-2010 2011, New York: Treatment Action Group.
20. Drugs for Neglected Diseases Initiative Transforming individual successes into sustainable change to ensure health innovation for neglected patients: why an essential health R&D convention is needed 2012, Geneva: DNDi Policy Brief, [http://www.dndi.org], Drugs for Neglected Diseases Initiative.
21. Moran M, Guzman J, Ropars A-L, McDonald A, Jameson N, Omune B, Ryan S, Wu L. Neglected disease research and development: how much are we really spending?. PLoS Med 2009, 6:e30. 10.1371/journal.pmed.1000030, 2634791, 19192946.
22. CEWG Research and Development to Meet Health Needs in Developing Countries: Strengthening Global Financing and Coordination 2012, Geneva: WHO, [http://www.who.int/phi/news/cewg_2011/en/], CEWG.
23. Barsdorf N. South Africa's Duty to Support Health Research for the Global Poor. Dissertation for the degree PhD thesis 2012, 60. University of Bergen: Centre for International Health.
24. G-FINDER Public Search Tool 2012, London: Policy Cures, [http://g-finder.policycures.org/gfinder_report/search.jsp], G-FINDER.
25. WHO Health and Human Rights Section 2012, Geneva: WHO, [http://www.who.int/hhr/en/], WHO.
26. Miller R. Globalizing Justice: The Ethics of Poverty and Power 2010, New York: Oxford University Press.
27. Pogge T. World Poverty and Human Rights: Cosmopolitan Responsibilities and Reforms 2002, Cambridge: Polity Press.
28. Data on GDP and GERD obtained from the OECD statistical database http://stats.oecd.org/.
29. OAU Abuja Declaration on HIV/AIDS, Tuberculosis and Other Related Infectious Diseases. Document OAU/SPS/ABUJA/3 2001, Organisation of African Unity, [http://www.un.org/ga/aids/pdf/ abuja_declaration.pdf], OAU.
30. Global Forum for Health Research Monitoring Financial Flows for Health Research 2008, Geneva: Global Forum for Health Research, Global Forum for Health Research.
31. National Department of Health National Health Research Summit Report 2011, Pretoria: , [http://www.doh.gov.za/docs/reports/2012/summitreport.pdf], National Department of Health.
32. Walwyn D. Determining research and development expenditure targets based on an affordability index. Inter J Innov Technol Management 2010, 7(2):183-191.
33. Verbeek A, Lykogianni E. A time series analysis of the development in national R&D intensities and national public expenditures on R&D. Final study report for specific assignment 4: literature review, feasibility study, collection of field statistics, calculation of indicators, survey, conclusions 2008, Brussels: Rindicate, [http://ec.europa.eu/invest-in-research/pdf/ download_en/ spa4_final_report_final.pdf].
34. Godin B. The Most Cherished Indicator: Gross Domestic Expenditures on R&D. Project on the History and Sociology of S&T Statistics, Working Paper no. 22 2003, Quebec: CSIIC.
35. Wells WA, Fan Ge C, Patel N, Oh T, Gardiner E, Kimerling ME. Size and usage patterns of private TB drug markets in the high-burden countries. PLoS One 2011, 6(5):e18964. 10.1371/journal.pone.0018964, 3087727, 21573227.